328.97 USD
+4.67 (+1.44%)
328.97 USD
0 (0%)
AMGN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. AMGN has an excellent profitability rating, but there are concerns on its financial health. AMGN has a correct valuation and a medium growth rate. AMGN also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
- In the past year AMGN was profitable.
- AMGN had a positive operating cash flow in the past year.
- Each year in the past 5 years AMGN has been profitable.
- In the past 5 years AMGN always reported a positive cash flow from operatings.
1.2 Ratios
- With an excellent Return On Assets value of 7.77%, AMGN belongs to the best of the industry, outperforming 92.99% of the companies in the same industry.
- The Return On Equity of AMGN (72.82%) is better than 99.05% of its industry peers.
- The Return On Invested Capital of AMGN (15.39%) is better than 96.02% of its industry peers.
- AMGN had an Average Return On Invested Capital over the past 3 years of 13.04%. This is significantly below the industry average of 18.28%.
- The last Return On Invested Capital (15.39%) for AMGN is above the 3 year average (13.04%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.77% | ||
| ROE | 72.82% | ||
| ROIC | 15.39% |
ROA(3y)7.14%
ROA(5y)8.52%
ROE(3y)118.78%
ROE(5y)104.3%
ROIC(3y)13.04%
ROIC(5y)14.18%
1.3 Margins
- AMGN's Profit Margin of 19.47% is amongst the best of the industry. AMGN outperforms 93.18% of its industry peers.
- In the last couple of years the Profit Margin of AMGN has declined.
- AMGN has a Operating Margin of 33.57%. This is amongst the best in the industry. AMGN outperforms 97.16% of its industry peers.
- AMGN's Operating Margin has declined in the last couple of years.
- The Gross Margin of AMGN (72.06%) is better than 82.58% of its industry peers.
- AMGN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.57% | ||
| PM (TTM) | 19.47% | ||
| GM | 72.06% |
OM growth 3Y-6.36%
OM growth 5Y-7.03%
PM growth 3Y-18.6%
PM growth 5Y-18.28%
GM growth 3Y-2.94%
GM growth 5Y-3.32%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMGN is still creating some value.
- AMGN has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for AMGN has been reduced compared to 5 years ago.
- AMGN has a better debt/assets ratio than last year.
2.2 Solvency
- The Debt to FCF ratio of AMGN is 4.28, which is a neutral value as it means it would take AMGN, 4.28 years of fcf income to pay off all of its debts.
- AMGN's Debt to FCF ratio of 4.28 is amongst the best of the industry. AMGN outperforms 92.23% of its industry peers.
- A Debt/Equity ratio of 5.45 is on the high side and indicates that AMGN has dependencies on debt financing.
- AMGN has a Debt to Equity ratio of 5.45. This is amonst the worse of the industry: AMGN underperforms 80.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.45 | ||
| Debt/FCF | 4.28 | ||
| Altman-Z | N/A |
ROIC/WACC1.79
WACC8.58%
2.3 Liquidity
- AMGN has a Current Ratio of 1.28. This is a normal value and indicates that AMGN is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.28, AMGN is doing worse than 83.14% of the companies in the same industry.
- AMGN has a Quick Ratio of 1.28. This is a bad value and indicates that AMGN is not financially healthy enough and could expect problems in meeting its short term obligations.
- AMGN's Quick ratio of 0.99 is on the low side compared to the rest of the industry. AMGN is outperformed by 85.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
- AMGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.79%, which is quite good.
- Measured over the past 5 years, AMGN shows a small growth in Earnings Per Share. The EPS has been growing by 5.97% on average per year.
- The Revenue has grown by 10.56% in the past year. This is quite good.
- AMGN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.43% yearly.
EPS 1Y (TTM)13.79%
EPS 3Y5.02%
EPS 5Y5.97%
EPS Q2Q%1.08%
Revenue 1Y (TTM)10.56%
Revenue growth 3Y8.76%
Revenue growth 5Y7.43%
Sales Q2Q%12.4%
3.2 Future
- AMGN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.77% yearly.
- AMGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.63% yearly.
EPS Next Y9.46%
EPS Next 2Y6.31%
EPS Next 3Y5.32%
EPS Next 5Y4.77%
Revenue Next Year9.43%
Revenue Next 2Y5.53%
Revenue Next 3Y4.57%
Revenue Next 5Y3.63%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 15.04, the valuation of AMGN can be described as correct.
- AMGN's Price/Earnings ratio is rather cheap when compared to the industry. AMGN is cheaper than 96.21% of the companies in the same industry.
- AMGN is valuated rather cheaply when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 14.69, the valuation of AMGN can be described as correct.
- Based on the Price/Forward Earnings ratio, AMGN is valued cheaply inside the industry as 96.02% of the companies are valued more expensively.
- AMGN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.04, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.04 | ||
| Fwd PE | 14.69 |
4.2 Price Multiples
- AMGN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AMGN is cheaper than 95.83% of the companies in the same industry.
- 97.16% of the companies in the same industry are more expensive than AMGN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.89 | ||
| EV/EBITDA | 12.44 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- The decent profitability rating of AMGN may justify a higher PE ratio.
PEG (NY)1.59
PEG (5Y)2.52
EPS Next 2Y6.31%
EPS Next 3Y5.32%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 3.05%, AMGN has a reasonable but not impressive dividend return.
- AMGN's Dividend Yield is rather good when compared to the industry average which is at 1.26. AMGN pays more dividend than 98.86% of the companies in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.92, AMGN pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.05% |
5.2 History
- The dividend of AMGN is nicely growing with an annual growth rate of 9.41%!
- AMGN has been paying a dividend for at least 10 years, so it has a reliable track record.
- AMGN has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)9.41%
Div Incr Years13
Div Non Decr Years13
5.3 Sustainability
- AMGN pays out 17.20% of its income as dividend. This is a sustainable payout ratio.
- AMGN's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP17.2%
EPS Next 2Y6.31%
EPS Next 3Y5.32%
328.97
+4.67 (+1.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-03 2026-02-03/amc
Inst Owners83.87%
Inst Owner Change-0.04%
Ins Owners0.06%
Ins Owner Change-0.77%
Market Cap177.14B
Revenue(TTM)35.97B
Net Income(TTM)7.00B
Analysts72.2
Price Target334.67 (1.73%)
Short Float %2.63%
Short Ratio5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.05% |
Yearly Dividend9.01
Dividend Growth(5Y)9.41%
DP17.2%
Div Incr Years13
Div Non Decr Years13
Ex-Date02-13 2026-02-13 (2.52)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.96%
Min EPS beat(2)10.28%
Max EPS beat(2)11.64%
EPS beat(4)4
Avg EPS beat(4)9.04%
Min EPS beat(4)2.49%
Max EPS beat(4)11.73%
EPS beat(8)7
Avg EPS beat(8)5.13%
EPS beat(12)10
Avg EPS beat(12)4.44%
EPS beat(16)14
Avg EPS beat(16)4.21%
Revenue beat(2)2
Avg Revenue beat(2)2.59%
Min Revenue beat(2)0.68%
Max Revenue beat(2)4.49%
Revenue beat(4)3
Avg Revenue beat(4)1.17%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)4.49%
Revenue beat(8)3
Avg Revenue beat(8)-0.21%
Revenue beat(12)4
Avg Revenue beat(12)-0.48%
Revenue beat(16)5
Avg Revenue beat(16)-0.54%
PT rev (1m)0.48%
PT rev (3m)4.6%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)-7.7%
EPS NY rev (1m)0.02%
EPS NY rev (3m)0.93%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)1.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.04 | ||
| Fwd PE | 14.69 | ||
| P/S | 4.92 | ||
| P/FCF | 13.89 | ||
| P/OCF | 13.5 | ||
| P/B | 18.42 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.44 |
EPS(TTM)21.87
EY6.65%
EPS(NY)22.4
Fwd EY6.81%
FCF(TTM)23.69
FCFY7.2%
OCF(TTM)24.38
OCFY7.41%
SpS66.8
BVpS17.86
TBVpS-59.79
PEG (NY)1.59
PEG (5Y)2.52
Graham Number93.76
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.77% | ||
| ROE | 72.82% | ||
| ROCE | 17.67% | ||
| ROIC | 15.39% | ||
| ROICexc | 17.86% | ||
| ROICexgc | 61.56% | ||
| OM | 33.57% | ||
| PM (TTM) | 19.47% | ||
| GM | 72.06% | ||
| FCFM | 35.46% |
ROA(3y)7.14%
ROA(5y)8.52%
ROE(3y)118.78%
ROE(5y)104.3%
ROIC(3y)13.04%
ROIC(5y)14.18%
ROICexc(3y)15.77%
ROICexc(5y)17.27%
ROICexgc(3y)75.76%
ROICexgc(5y)77.1%
ROCE(3y)14.97%
ROCE(5y)16.28%
ROICexgc growth 3Y3.26%
ROICexgc growth 5Y-18.2%
ROICexc growth 3Y-8.67%
ROICexc growth 5Y-7.85%
OM growth 3Y-6.36%
OM growth 5Y-7.03%
PM growth 3Y-18.6%
PM growth 5Y-18.28%
GM growth 3Y-2.94%
GM growth 5Y-3.32%
F-Score7
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.45 | ||
| Debt/FCF | 4.28 | ||
| Debt/EBITDA | 2.97 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.3% | ||
| Profit Quality | 182.08% | ||
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | N/A |
F-Score7
WACC8.58%
ROIC/WACC1.79
Cap/Depr(3y)24.77%
Cap/Depr(5y)23.42%
Cap/Sales(3y)3.59%
Cap/Sales(5y)3.31%
Profit Quality(3y)165.92%
Profit Quality(5y)155.23%
High Growth Momentum
Growth
EPS 1Y (TTM)13.79%
EPS 3Y5.02%
EPS 5Y5.97%
EPS Q2Q%1.08%
EPS Next Y9.46%
EPS Next 2Y6.31%
EPS Next 3Y5.32%
EPS Next 5Y4.77%
Revenue 1Y (TTM)10.56%
Revenue growth 3Y8.76%
Revenue growth 5Y7.43%
Sales Q2Q%12.4%
Revenue Next Year9.43%
Revenue Next 2Y5.53%
Revenue Next 3Y4.57%
Revenue Next 5Y3.63%
EBIT growth 1Y93.73%
EBIT growth 3Y1.84%
EBIT growth 5Y-0.13%
EBIT Next Year42.71%
EBIT Next 3Y11.36%
EBIT Next 5Y7.69%
FCF growth 1Y36%
FCF growth 3Y7.44%
FCF growth 5Y4.03%
OCF growth 1Y24.04%
OCF growth 3Y7.45%
OCF growth 5Y4.66%
AMGEN INC / AMGN FAQ
Can you provide the ChartMill fundamental rating for AMGEN INC?
ChartMill assigns a fundamental rating of 5 / 10 to AMGN.
What is the valuation status of AMGEN INC (AMGN) stock?
ChartMill assigns a valuation rating of 6 / 10 to AMGEN INC (AMGN). This can be considered as Fairly Valued.
What is the profitability of AMGN stock?
AMGEN INC (AMGN) has a profitability rating of 7 / 10.
How financially healthy is AMGEN INC?
The financial health rating of AMGEN INC (AMGN) is 3 / 10.
What is the earnings growth outlook for AMGEN INC?
The Earnings per Share (EPS) of AMGEN INC (AMGN) is expected to grow by 9.46% in the next year.